Mablife
Records under this name other than the patents Mablife holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 4 of 4 · Back to Mablife
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,153,506 | Use of anti-ferritin monoclonal antibodies in the treatment of some cancers Term ended Term ended Jan 7, 2022 · From the USPTO record | Term ended | Term ended Jan 7, 2022 | From the USPTO record |
| US 8,728,477 | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof Formerly held Lapsed on the fee record Ended May 20, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 20, 2018 | From the USPTO record |
| US 8,409,573 | ANTI-CD71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells Lapsed on the fee record Ended Apr 2, 2017 · High confidence | Lapsed on the fee record | Ended Apr 2, 2017 | High confidence |
| US 7,736,647 | ANTI-CD71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells Lapsed on the fee record Ended Jun 15, 2014 · High confidence | Lapsed on the fee record | Ended Jun 15, 2014 | High confidence |